CLAIMS

1. A product comprising an antibiotic agent and cysteamine, wherein the antibiotic is not Tobramycin, Colistin, Gentamicin or Ciprofloxacin.

2. The product as claimed in claim 1, wherein the antibiotic agent is a peptide or non-peptide antibiotic.

3. The product as claimed in claim 2, wherein the peptide antibiotic is colistin, bacitracin or polymyxin B.

4. The product as claimed in claim 2, wherein the non-peptide antibiotic is of the group consisting of aminoglycosides, ansamycins, carbacephem, carbapenems cephalosporins, lincosamides, macrolides, monobactams, nitrofurans, quinolones, penicillin, sulfonamides and tetracyclin

5. A product as claimed in any of the preceding claims comprising a synergistically effective amount of (i) an antibiotic agent, and (ii) cysteamine.

6. A product as claimed in any of the preceding claims for use as a medicament.

7. A substrate to which a product as claimed in any of the preceding claims is applied or attached.

8. The substrate as claimed in claim 7, wherein the substrate is selected from the group consisting of dressings, medical devices and indwelling devices.

9. The substrate as claimed in claim 8, wherein the indwelling device is selected from the group consisting of stents, catheters, peritoneal dialysis tubing, draining devices, joint prostheses and dental implants.

10. A pharmaceutical composition comprising a product as claimed in any of clams 1 to 6 and one or more pharmaceutically acceptable diluents, excipients and/or carriers.

11. Use of a product as claimed in any of claims 1 to 6 in the manufacture of a medicament for the treatment or prevention of a microbial infection or disease or condition associated therewith.

12. The use as claimed in claim 12, wherein infection, or disease or condition associated therewith, is selected from the group consisting of skin and wound infections, middle-ear infections, gastrointestinal tract infections, peritoneal membrane infections, urogenital tract infections, oral soft tissue infections, formation of dental plaque, eye infections, endocarditis, infections in cystic fibrosis, and infections of indwelling medical devices.

13. The use as claimed in claim 11 or 12, wherein the infection is of a mucolytic environment.

14. The use as claimed in claim 13, wherein the infection is a bacterial infection associated with cystic fibrosis.

15. The use as claimed in any one of claims 11 to 14, wherein the infection is caused by a bacterium selected from the group consisting of *Pseudomonas* spp., *Staphylococcus* spp., *Haemophilus* spp., *Burkholderia* spp., *Streptococcus* spp. and *Propionibacterium* spp.

16. The use as claimed in claim 15, wherein the bacterium is *Pseudomonas* spp.

17. The use as claimed in claim 15, wherein the bacterium is *Burkholderia* spp.

18. The use as claimed in claim 15, wherein the bacterium is *Staphylococcus* spp.

19. The use as claimed in claims 12-19, wherein the treatment is to be administered separately, sequentially or in combination in a therapeutically effective amount of:

- the antibiotic agent; and
- cysteamine.

20. The use as claimed in claim 11, wherein the microbial infection is a topical infection or a systemic infection.

21. The use as claimed in claim 20, wherein the systemic infection is a mucosal infection.

22. The use as claimed in claim 21, wherein the mucosal infection is a gastrointestinal, urogenital or respiratory infection.

23. The use as claimed in claim 21 or 22, wherein the mucosa infection is cystic fibrosis or is associated with chronic obstructive pulmonary disease (COPD).